Effect of Vitamin D3 on Brain Waves in Male Parkinson's Patients With Low Vitamin D: A qEEG Study
Effect of Vitamin D3 Supplementation on Brain Waves in Male Parkinson's Disease Patients With Hypovitaminosis D : A Quantitative Electroencephalogram Analysis
Bangladesh Medical University
15 participants
Jul 15, 2025
INTERVENTIONAL
Conditions
Summary
This is an experimental study (Interventional self-controlled trial, pretest-posttest design). The goal of this clinical trial is to evaluate the effect of vitamin D3 supplementation on quantitative EEG in male Parkinson's disease patients with hypovitaminosis D. The main question it aims to answer is: Vitamin D3 supplementation has effect on brain waves in male Parkinson's disease patients with hypovitaminosis D. Researcher will compare the effect of vitamin D3 supplementation on brain waves in male Parkinson's disease patients with hypovitaminosis D with their pre intervention ( baseline ) condition on brain waves to assess whether there will be any improvement of brain electrical activity by quantitative electroencephalogram (QEEG). Participants will : Take vitamin D3 orally for 8 weeks (50,000 IU/week) Visit the medical university after 8 weeks for evaluation of serum 25(OH)D level and QEEG Must bring the empty strips of vitamin D supplement with them during their visit.
Eligibility
Inclusion Criteria5
- Male Patients with PD up to stage 3 according to Hoehn and Yahr (H-Y) scale
- Age: 51years to70 years
- BMI: 18.5-24.9 kg/m2
- Hypovitaminosis D (Serum 25(OH)D level \<30 ng/ml)
- Patients on Levodopa therapy
Exclusion Criteria13
- Already taking vitamin D3 supplements
- Current use of medication/substances known to affect neuronal excitability or EEG patterns, such as - sedatives, antidepressant, antipsychotics, alcohol.
- Patients who are currently suffering from following diseases
- Neurological disorders (Migraine, epilepsy)
- Cardiovascular disorders (Myocardial infarction, hypertension, cardiac arrhythmia, heart failure)
- Respiratory disorders (Bronchial asthma, COPD)
- Psychiatric illness (e.g., schizophrenia, major depression, bipolar disorder, severe dementia)
- With biochemical evidence of-
- Hypercalcemia
- Renal insufficiency
- Liver diseases
- Endocrine disorders (uncontrolled diabetes mellitus, Hypothyroidism, Hyperthyroidism)
- Active smoker
Interventions
Administration of vitamin D3 capsule 50,000 IU/week for 8 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07096336